Gleevec Sales Data

Rank 24 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Gleevec U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 24 (1) 7.22% 3.85%
Q3 2013 25 (1) -1.68% -11.36%
Q2 2013 24 (2) 7.85% 7.32%
Q1 2013 26 0.41% -5.75%
Q4 2012 26 (1) -4.10% -5.43%
Q3 2012 25 (9) 10.57% 9.52%
Q2 2012 34 (4) 5.21% 6.33%
Q1 2012 38 (2) 0.13% -8.14%
Q4 2011 36 (1) 4.38% 3.61%
Q3 2011 35 (2) 5.88% -2.35%
Q2 2011 37 (3) 1.64% 1.19%
Q1 2011 40

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
January 12, 2012Kedem Pharmaceuticals Initiates Development of Sublingual Anti-Cancer Drug, Gleevec
March 22, 2011Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
October 19, 2010Some With Once-Deadly Leukemia Can Take a Break From Gleevec
September 21, 2010Staying on Gleevec Seems to Help Gastro Cancer Patients
January 8, 2010Study Suggests Way to 'Mop Up' Leukemia Cells
October 20, 2009Cancer Drug May Help Scleroderma
March 19, 2009Gleevec Prevents Return of Intestinal Cancer, Study Confirms
November 18, 2008Cancer Drugs May Treat Type 1 Diabetes
Hide
(web2)